clinical trial · NCT07805356
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Calcilytix Therapeutics, Inc., a BridgeBio company·phase3·not yet recruiting·n = 160
HypoparathyroidismChronic HypoparathyroidismEncaleretPlacebo
brief summary
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
started
Aug 31, 2026
primary completion
Jan 1, 2028
completion
Jan 1, 2033
last updated
Sep 4, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Investigating Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol